改进的静脉静脉基因基因疗法基于内皮特异性促进体驱动的因子VIII表达为血友病A
Jie Gong1,2, Rui Yang2, Min Zhou1
1Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 611731, China.
Molecular medicine (Cambridge, Mass.)
|June 12, 2023
概括
基因疗法为A型血友病 (HA) 提供了一个有希望的替代方案. 研究人员开发了针对第八因子 (FVIII) 表达的lentiviral vectors (LVs),其中LV-VEC-F8BDD在临床前模型中显示出显著的治疗潜力和低免疫性.
科学领域:
- 基因治疗 基因治疗
- 血液学 血液学 血液学
- 分子生物学分子生物学
背景情况:
- 血友病A (HA) 是由第八因子 (FVIII) 缺乏引起的遗传性疾病.
- 目前用于HA的蛋白质替代疗法 (PRT) 具有短期有效性和高成本等局限性.
- 基因疗法为HA治疗提供了一个有前途的替代方案.
研究的目的:
- 通过使用先进的lentiviral vector (LVs) 来研究向的FVIII表达.
- 评估不同组织特异性促进剂的FVIII传递的疗效和免疫性.
主要方法:
- 开发了具有通用 (EF1α) 或组织特异性促进体 (内皮特异性VEC,内皮/上皮特异性KDR,巨核细胞特异性Gp和ITGA) 的LV.
- 在人类细胞系和F8淘汰赛小鼠中测试了FVIII表达和活性.
- 在静脉静脉注射后评估表型纠正和抗FVIII免疫反应.
主要成果:
- LV-VEC-F8BDD和LV-ITGA-F8BDD在细胞系中显示了治疗性FVIII水平.
- 在小鼠中,静脉输送LV-VEC-F8BDD在180天内实现了80%的治疗FVIII活性.
- 与其他载体相比,LV-VEC-F8BDD显示出较低的免疫性和减少的抗FVIII反应.
结论:
- LV-VEC-F8BDD表现出高效率,内皮特异性和低免疫性.
- 这种载体在A型血友病治疗中具有显著的临床应用潜力.
相关概念视频
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...